Way ForwardClearly there are questions to be answered following the CC and Financials - Cedars-Sinai, final terms of CARE closing, the 100,000 patients, Aristotle sales, revenue breakdowns etc. This one will take a while to play out as it attempts to gain traction in the covid dominated and neglected cancer detection/treatment sphere. The market is there - its just a matter of ascertaining the extent that CARE will access this market with its clinics and telehealth. We need this as covid revenue is clearly drying up.
The sp is more than disappointing -$.37 cents for a company with this revenue and cash on hand is inexplicable - clearly the market has concerns with CARE as it tanked following the April announcement - its now up to the company to show that this strategy is a winner.
We will have to continue to put up with the comedy act from the socially depraved few here who insist on trying to cause dissension. They obviously believe Rome was built in a day.........